Polaryx Therapeutics, Inc. Common Stock
NASDAQ: PLYX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alex Yang
- Employees
- 11
- Headquarters
- Paramus, United States
- IPO year
- 2026
- Market cap
- $113.6M
- Website
- https://polaryx.com
Loading PLYX…
Loading profile data…Frequently asked questions about PLYX
What does Polaryx Therapeutics, Inc. Common Stock (PLYX) do?
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscino...
Where does PLYX trade?
Polaryx Therapeutics, Inc. Common Stock (PLYX) trades on the NASDAQ Global Market.
What sector is PLYX in?
Polaryx Therapeutics, Inc. Common Stock (PLYX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Polaryx Therapeutics, Inc. Common Stock?
Alex Yang is the chief executive officer of Polaryx Therapeutics, Inc. Common Stock (PLYX).
Where is Polaryx Therapeutics, Inc. Common Stock headquartered?
Polaryx Therapeutics, Inc. Common Stock is headquartered in United States.
Does PLYX pay a dividend?
Polaryx Therapeutics, Inc. Common Stock (PLYX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PLYX go public?
Polaryx Therapeutics, Inc. Common Stock (PLYX) completed its initial public offering in 2026.